Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia

International Journal of Cancer

Volumn 135, Issue 10, 2014, Pages 2370-2379

  Rissiek, Anne ^a   Schulze, Christian ^a   Bacher, Ulrike ^b   Schieferdecker, Aneta ^a   Thiele, Benjamin ^a   Jacholkowski, Anita ^a   Flammiger, Anna ^a   Horn, Christiane ^a   Haag, Friedrich ^a   Tiegs, Gisa ^a   Zirlik, Katja ^c   Trepel, Martin ^a   Tolosa, Eva ^a   Binder, Mascha ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CLL; MBL; Multidimensional analysis; Regulatory T cells; T cell profiling

Indexed keywords

AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD3+ CD56+ T CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING T CELL; COHORT ANALYSIS; CONTROLLED STUDY; DONOR; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; GRANULOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL B CELL LYMPHOCYTOSIS; MONOCYTE; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRINCIPAL COORDINATE ANALYSIS; PROGNOSIS; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; T CELL SCORE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; BLOOD; CASE CONTROL STUDY; CLL; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; IMMUNOLOGY; MBL; MIDDLE AGED; MORTALITY; MULTIDIMENSIONAL ANALYSIS; MULTIVARIATE ANALYSIS; PATHOLOGY; REGULATORY T-CELLS; SURVIVAL RATE; T-CELL PROFILING;

CLL; MBL; MULTIDIMENSIONAL ANALYSIS; REGULATORY T-CELLS; T-CELL PROFILING;

AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84909981772     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28884     Document Type: Article

References (45)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-29.
2. Dagklis A, Fazi C, Scarfo L, et al. Monoclonal B lymphocytosis in the general population. Leuk Lymphoma 2009;50:490-2.
3. Fazi C, Scarfo L, Pecciarini L, et al. General population low-count CLL-like MBL persist over time without clinical progression, though carrying the same cytogenetic abnormalities of CLL. Blood 2011;118:6618-25.
4. Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood 2012;119:4358-62.
5. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575-83.
6. Rawstron AC, Shanafelt T, Lanasa MC, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 2010;78 (Suppl 1):S19-S23.
7. Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010;24:512-20.
8. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463-72.
9. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
10. Christopoulos P, Pfeifer D, Bartholome K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011;117:3836-46.
11. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-65.
12. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-35.
13. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:431-8.
14. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-80.
15. Yellin MJ, Sinning J, Covey LR, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666-74.
16. Dazzi F, D'Andrea E, Biasi G, et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 1995;75:26-32.
17. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
18. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev 1996;10:111-27.
19. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9.
20. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007;178:5595-605.
21. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006;103:1041-6.
22. Pallasch CP, Ulbrich S, Brinker R, et al. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009;33:460-4.
23. Cantwell M, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997;3:984-9.
24. Ramsay AG, Clear AJ, Fatah R, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120:1412-21.
25. Ramsay AG, Evans R, Kiaii S, et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013;121:2704-14.
26. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 2009;94:1198-202.
27. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37.
28. D'Arena G, D'Auria F, Simeon V, et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012;87:628-31.
29. D'Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011;35:363-8.
30. D'Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011;24:915-23.
31. D'Arena G, Simeon V, D'Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? Am J blood Res 2013;3:52-7.
32. Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. Leuk Lymphoma 2009;50:687-8.
33. Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163-9.
34. Coscia M, Vitale C, Peola S, et al. Dysfunctional Vgamma9Vdelta2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood 2012;120:3271-9.
35. R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013. Available at: http://www.R-project.org/.
36. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008;141:607-14.
37. Eisele L, Haddad T, Sellmann L, et al. Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. Leuk Res 2009;33:775-8.
38. Perry C, Hazan-Halevy I, Kay S, et al. Increased CD39 expression on CD4(1) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann Hematol 2012;91:1271-9.
39. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612-21.
40. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2012;27:136-41.
41. Koch S, Larbi A, Derhovanessian E, et al. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 2008;5:6.
42. Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol 2011;155:457-67.
43. Lee BN, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011;117:3999-4008.
44. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009;106:6250-5.
45. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-73.